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Abstract
Heart failure is the common final pathway of several cardiovascular conditions and a 
major cause of morbidity and mortality worldwide. Aberrant activation of the adap-
tive immune system in response to myocardial necrosis has recently been implicated 
in the development of heart failure. The ß-adrenergic agonist isoproterenol hydro-
chloride is used for its cardiac effects in a variety of different dosing regimens with 
high doses causing acute cardiomyocyte necrosis. To assess whether isoproterenol-
induced cardiomyocyte necrosis triggers an adaptive immune response against the 
heart, we treated C57BL/6J mice with a single intraperitoneal injection of isoprotere-
nol. We confirmed tissue damage reminiscent of human type 2 myocardial infarction. 
This is followed by an adaptive immune response targeting the heart as demonstrated 
by the activation of T cells, the presence of anti-heart auto-antibodies in the serum as 
late as 12 weeks after initial challenge and IgG deposition in the myocardium. All of 
these are hallmark signs of an established autoimmune response. Adoptive transfer 
of splenocytes from isoproterenol-treated mice induces left ventricular dilation and 
impairs cardiac function in healthy recipients. In summary, a single administration of 
a high dose of isoproterenol is a suitable high-throughput model for future studies 
of the pathological mechanisms of anti-heart autoimmunity and to test potential im-
munomodulatory therapeutic approaches.
K E Y W O R D S
adaptive immune system, auto-antibodies, autoimmunity, fibrosis, inflammation, isoprenaline, 
isoproterenol, myocardial infarction, type 2 myocardial infarction
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1  | INTRODUC TION
Type 2 myocardial infarction (T2MI) is a heterogeneous syndrome 
resulting in ischaemic damage to the heart because of insufficient 
myocardial oxygen supply.1,2 Unlike type 1 MI (T1MI), T2MI occurs in 
the absence of coronary artery disease (CAD) or the disruption of an 
atherosclerotic plaque. Instead, other conditions including hypoxae-
mia, hypo/hypertension, tachycardia or tachyarrhythmias lead to an 
imbalance between myocardial oxygen supply and demand, culmi-
nating in cardiomyocyte necrosis.3,4 Importantly, T2MI is still an un-
der-recognised clinical entity, despite a recent estimate that 58% of 
total MI patients in fact suffer from T2MI.5 The development of high 
sensitivity biomarker assays for cardiac troponin I, which allow the 
detection of even mildly elevated levels of cardiac troponin in the 
absence of CAD or a T1MI diagnosis, has made the discrimination 
between T1MI and T2MI possible.6 T2MI patients face poor short- 
and long-term outcomes and a heart failure risk equal to T1MI.7,8 
Heart failure, the final common pathway of a range of cardiovascular 
conditions, affects up to 62.7% of MI patients within 6 years after 
infarction.9
Myocardial necrosis triggers an immediate response by the 
innate immune system which is crucial for quick tissue repair.10 
However, excessive inflammation is a potent pathological factor in 
heart failure and has been studied extensively.11–13 Recently, it has 
also been suggested that the adaptive immune system is activated 
after MI and may play a role in the deterioration of heart function 
and the development towards heart failure.14–17 However, patholog-
ical mechanisms are far from understanding and there is an urgent 
need for better recognition and understanding of these immunolog-
ical processes, if they are to become the target of future therapeutic 
applications.
Investigation of the adaptive immune response to cardiac 
damage is highly complex and still relies heavily on in vivo ex-
perimentation. In rodents, surgical coronary artery ligation of 
the left anterior descending artery (LAD) is the most commonly 
used experimental model for human T1MI,18 whereas a dedicated 
model for T2MI is missing. The use of the ß-adrenergic agonist iso-
proterenol to induce cardiomyocyte necrosis has been described 
over 50 years ago in rats 19,20 and has been characterised exten-
sively.21,22 It now routinely serves as a long-term low-dose treat-
ment to induce cardiac hypertrophy,23–25 and few research groups 
have also used it to induce acute infarct-like necrotic lesions by 
injection of high doses.26–28 Importantly, the isoproterenol model 
recapitulates several of the salient features of T2MI. The acute 
ß-adrenergic activation has a strong positive inotropic and chro-
notropic effect,29 leading to increased oxygen demand, dysregu-
lation of ryanodine receptor 2 (RyR2) and consequent intracellular 
calcium leakage.27 These are all factors that contribute to cardio-
myocytes necrosis and acute myocardial injury.
Here, we characterise the effects of a single high dose of 
isoproterenol on the adaptive immune response to ischaemic 
myocardial damage in C57BL/6J mice. We confirm that isoprotere-
nol-induced myocardial necrosis is severe enough to trigger immune 
activation and replacement fibrosis. We show that this cardiac injury 
activates CD4+ helper T cells and subsequently induces persistent 
IgG+ anti-heart auto-antibody production. A single high dose of iso-
proterenol is therefore a simple, resource-efficient and minimally 
invasive model of T2MI to investigate the role of post-MI anti-heart 
autoimmunity.
2  | MATERIAL S AND METHODS
Mice: All animal procedures carried out at Imperial College London 
were approved by the Imperial College Governance Board for Animal 
Research and in accordance with the UK Home Office Animals 
(Scientific Procedures) Act 1986 and Directive 2010/63/EU of the 
European Parliament on the protection of animals used for scientific 
purposes. All animal works carried out at The Jackson Laboratories 
were approved by The Jackson Laboratory Institutional Animal Care 
and Use Committee and were in accordance with national and inter-
national regulations. Mice used were 8- to 12-week-old male or fe-
male C57BL/6J mice; within each experiment, experimental groups 
were age- and sex-matched. Mice were purchased from Charles 
River UK (Imperial College London) or bred in house (The Jackson 
Laboratories). After random allocation to experimental groups, mice 
were housed under SPF conditions (Imperial College London) or in 
conventional cages (The Jackson Laboratories) in temperature-con-
trolled facilities on a 12-h light/dark cycle on standard diet.
Isoproterenol treatment and tissue harvest: Mice were treated 
with isoproterenol HCL (Sigma-Aldrich, St. Louis, MO, USA) in 
Dulbecco's phosphate-buffered saline (DPBS; Sigma-Aldrich) by a 
single intraperitoneal injection of 160 mg/kg. Control mice were 
treated with DPBS at equivalent volume. On the day of tissue col-
lection, 200 μl blood was collected. Blood was incubated on ice for 
30 minutes and then centrifuged for 3 minutes at max rcf for serum 
collection. Organs were isolated after in situ perfusion with ice-cold 
DPBS supplemented with 0.9 mM CaCl2 through the apex of the left 
ventricle of the heart to clear blood from heart chambers and blood 
vessels.
Adoptive transfer: Donor mice were treated with isoprotere-
nol HCL (Sigma-Aldrich, St. Louis, MO, USA) in DPBS by a single 
intraperitoneal injection of 160 mg/kg. 4 weeks after isoprotere-
nol injection, serum and spleens were harvested. Excised spleens 
were mashed through a 70μm cell strainer to generate single-cell 
suspensions, followed by red blood cell lysis using Red Blood Cell 
Lysis Buffer (Sigma-Aldrich, St. Louis, MO, USA). CD4+ T cells 
were enriched using the EasySep™ Mouse CD4+ T Cell Isolation 
Kit (STEMCELL Technologies, Cambridge, UK) as per the manufac-
turer's instructions. Recipient mice were pre-treated 24h before 
adoptive transfer with a single topical application to the right ear 
of 3.3μg/μl/g bodyweight (in 1:3 ethanol:acetone) of Resiquimod 
(Sigma-Aldrich, Dorset, UK). Recipients received a single intrave-
nous injection of either PBS, 3x107 control splenocytes, 3x107 
isoproterenol splenocytes, 1x107 CD4+ T cells or twice-weekly in-
traperitoneal injection of 200ul isoproterenol serum for 2 weeks, 
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respectively. Pathological effects of adoptive transfers were ana-
lysed after 4 weeks.
Cardiac magnetic resonance imaging (MRI): Longitudinal car-
diac MRI was performed before and 2 weeks post-isoprotere-
nol injection. Mice were anaesthetised with 1%-2.5% isoflurane 
adjusted to maintain the respiratory rate of 65-75 breaths/min. 
Body temperature was maintained at 37 ± 0.5°C by a heating mat. 
Respiration, ECG and body temperature were continuously moni-
tored (SA Instruments, Stony Brook, NY, USA). MRI was performed 
on a 9.4 T-BioSpec system (Bruker BioSpin, Ettlingen, Germany) 
equipped with a mouse heart array receiver. For localisation of 
the heart, low-resolution ECG and respiratory triggered gradi-
ent-echo scout scans were initially acquired in axial, sagittal and 
coronal orientations followed by highly resolved vertical long-axis 
(VLA) and horizontal long-axis (HLA) views. Ejection fraction (EF), 
end-diastolic volume (EDV), end-systolic volume (ESV) and mass 
were quantified from a multi-slice multi-frame CINE sequence 
with slices oriented in short axis covering the entire left ventri-
cle (LV), making sure to include the mitral annulus and the apex. 
Acquisition parameters are as follows: repetition time (TR)=RR 
interval/number of frames (∼10 ms for 11 frames), TReffective = RR 
interval, echo time (TE) = 2.05 ms, flip angle = 25°, slice thick-
ness = 1 mm (continuous slices), acquisition matrix = 122 × 122 
and field of view = 20 × 20 mm2, leading to a spatial in-plane res-
olution of 164 × 164 μm2.
Echocardiography: The high-frequency ultrasound system Vevo 
770 (VisualSonics Inc, Toronto, Canada) with a 30-MHz linear trans-
ducer was used for transthoracic echocardiography. Anaesthesia 
was induced at 1%-2% isoflurane, and warmed ultrasound gel and a 
heating pad were used to maintain body temperature at 37 ± 0.5°C 
and heart rate at 450 ± 50 beats per minute. Left ventricular (LV) 
parameters were calculated from M-mode traces at base, mid-level 
and apex in parasternal long- and short-axis views. Analysis was per-
formed using the Vevo 770 workstation software.
Histology and scoring of damage parameters: Organs were ex-
cised as described above, fixed in 10% neutral buffered formalin 
overnight and stored in 70% ethanol. For wax-embedding and his-
tology, tissue samples were dehydrated in an increasing gradient of 
ethanol and embedded in paraffin. Five-µm sections were cut and 
de-waxed and rehydrated in an ethanol gradient. Sections were 
stained with haematoxylin and eosin (H&E) and Picrosirius Red. All 
reagents were purchased from Sigma-Aldrich (Sigma-Aldrich, Dorset, 
UK). Semi-quantitative scoring of heart sections was performed as 
established previously.30 H&E-stained sections were used to analyse 
and score immunopathology. Picrosirius Red staining was used to 
analyse and score fibrosis. Individual parameters were scored on a 
scale of 0 (none), 1 (mild), 2 (moderate) to 3 (severe). Scores were 
obtained from 4 areas each on 2 midline cross sections per animal 
by a blinded researcher. Images were captured using a Hamamatsu 
NanoZoomer 2.0 slide scanner (Hamamatsu, San Jose, CA, US) and a 
LMD7000 microscope (Leica microsystems, Milton Keynes, UK) and 
processed for quantification of nuclei (cell count) and area of fibro-
sis using NDP.view2 Plus Image viewing software (Hamamatsu, San 
Jose, CA, US) and the public domain software ImageJ (NIH; http://
rsb.info.nih.gov).31
Cardiac troponin I and anti-heart auto-antibody ELISA: A mouse 
cardiac troponin I (cTnI) ELISA Kit (MyBioSource, San Diego, CA, USA) 
was used to determine cTnI concentrations in post-isoproterenol 
serum as instructed by the manufacturer. Serum samples were diluted 
two-fold in supplied diluent. A standard curve was generated to cal-
culate cTnI concentrations in pg/ml. The ELISA protocol for the detec-
tion of mouse anti-heart auto-antibodies was optimised as described 
previously.30 ELISA plates (SpectraMax Paradigm, Molecular Devices, 
UK) were coated with 50µl per well of 4µg/µl pig heart lysate (Novus 
Biologicals, Bio-Techne, Abingdon, UK) diluted in PBS overnight at 4 
ºC. Plates were washed 3 times for 5 minutes each with 200 µl per well 
of ELISA washing buffer. 50 µl of post-isoproterenol serum was added 
diluted 1:10 and 1:100 for overnight incubation at 4 ºC. Detection re-
agents were anti-mouse IgG-HRP (all from BioLegend, London, UK). 
Optical densities were measured at 450 nm using a SpectraMAX i3 
Microplate Reader (Molecular Devices, San Jose, CA, USA).
Heart and lymph node single-cell preparation: To generate sin-
gle-cell cardiac suspensions for flow cytometry, a modified digestion 
protocol was used as previously described.32 Hearts were excised, 
chopped 30 times with surgical scissors and placed in 3 ml digestion 
buffer. The digestion buffer consisted of 2 mg/ml collagenase type IV 
(Worthington Biochemical Corporation, Lakewood, NJ, USA), 1.2 U/
ml dispase II (Thermo Fisher Scientific, Waltham, MA, USA) and 16.6 
ul/ml precision count beads (BioLegend, San Diego, CA, USA) in DPBS 
supplemented with 0.9 mM CaCl2. The tissue was incubated at 37ºC 
for 15 minutes. After incubation, tissue was triturated 12 times. Tissue 
was incubated and triturated 2 more times for a total of 45 minutes. 
The final trituration was increased to 30. Tissue was filtered through 
sterile cheesecloth and washed with ice-cold DPBS supplemented 
with 0.9 mM CaCl2 for 20 minutes at 200 rcf at 4 ºC. Lymph nodes 
were incubated at 37ºC for 30 minutes in 3 ml and 0.5 ml digestion 
buffer, respectively. Lymphoid digestion buffer consisted of 0.24 U/mg 
400 Mandl U/ml collagenase D (Roche Diagnostics GmbH Mannheim, 
Germany) in FBS-free DMEM. Cells were washed twice in FACS buffer 
supplemented with 2% FBS spun for 5 minutes at 400 rcf at 4 ºC.
Flow cytometry: Single-cell preparations were used for flow 
cytometric analysis. Antibodies used were as follows: anti-mouse 
CD45 (CD45-APC-Cy7—cat. 103116, clone 30-F11, LOT B185138, 
dilution 1:800), anti-mouse CD3 (CD3-APC—cat. 100235, clone 
17A2, LOT B166471, dilution 1:200), anti-mouse CD4 (CD4-FITC—
cat. 115505, clone 6D5, LOT B131781, dilution 1:200), anti-mouse 
CD8a (CD8a-PE—cat. 101207, clone M1/70, LOT B166034, dilution 
1:400), anti-mouse CD62L (CD62L-AP—cat. 137607, clone 29A1.4, 
LOT B152186, dilution 1:200) and anti-mouse CD44 (CD44-APC—
cat. 137607, clone 29A1.4, LOT B152186, dilution 1:200). All were 
purchased from BioLegend (BioLegend, London, UK). Antibody dilu-
tions in cell staining buffer containing 1% TruStain fcX™ (antimouse 
CD16/32) antibody (both from BioLegend, London, UK) were used 
to stain according to the manufacturer's protocol. Samples were ac-
quired using a BD LSRII (Becton Dickinson, Oxford, UK) and analysed 
using FlowJo version 10.6.1 software (Tree Star, Ashland, OR, USA).31
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Immunohistochemistry: For the detection of in vivo antibody 
deposition in cardiac tissue, 5-µm sections of frozen post-isoprotere-
nol hearts were stained with goat anti-mouse IgG-FITC (cat. F5387, 
Sigma-Aldrich, Dorset, UK) and rat anti-mouse IgM-PE (cat. 406507, 
BioLegend, London, UK). Images were captured using a LMD7000 mi-
croscope (Leica microsystems, Milton Keynes, UK) and processed using 
the public domain software ImageJ (NIH; http://rsb.info.nih.gov).
Experimental planning and statistical analysis: Individual animals 
were randomly allocated to experimental groups from a homoge-
neous age- and sex-matched pool, husbandry and care was provided 
by blinded staff, and analysis was performed by a blinded researcher. 
Initial exploratory titration experiments used n = 3 for welfare rea-
sons. Subsequent experimental group sizes were defined based on 
the effect size of 3.8 achieved in infiltration scoring experiments. 
To achieve 95% power, with 0.05 set as alpha error, a group size of 
3 is necessary for the primary readouts of infiltration. Smaller ef-
fect sizes were expected and accepted as biologically significant for 
flow cytometry, MRI and ELISA results; thus, group sizes were in-
creased for these experiments. Statistical analysis was performed 
using GraphPad Prism 8, and data were presented as mean ± s.e.m 
throughout. Normal distribution of parametric data was tested using 
Shapiro-Wilk test. Comparison between 2 groups was performed 
using Student's t test with Welch's correction to account for pos-
sible differences in variation between control and treatment group. 
Comparison between multiple experimental groups was performed 
using one- or two-way ANOVA with Dunnett's multiple comparisons 
post hoc test to obtain multiplicity-adjusted p-values. Scoring data 
were analysed using non-parametric Kruskal-Wallis test with Dunn's 
multiple comparisons post hoc test to obtain multiplicity-adjusted 
p-values. Differences were considered significant at P < .05.
3  | RESULTS
3.1 | A single dose of isoproterenol induces cardiac 
histopathology reminiscent of human type-2 MI in 
C57BL/6J mice
Isoproterenol induces cardiomyocyte necrosis with necrotic car-
diomyocytes mostly localised in the sub-endocardium.33 Different 
mouse strains show variable susceptibility to induction of cardiac 
damage, and C57BL/6J mice have a robust cardiac phenotype rel-
atively resistant to myocardial fibrosis.34,35,36 They are however 
among the best characterised mouse strains and commonly used 
for genetic modification and immunological studies. To allow sub-
sequent use of this common mouse strain, we performed a dose 
titration experiment to investigate whether C57BL/6J mice were 
susceptible to developing cardiac lesions while maintaining high 
animal welfare standards. Male C57BL/6J mice were treated with 
a single bolus intra-peritoneal injection of increasing doses of iso-
proterenol starting with 40mg/kg up to 160mg/kg. Isoproterenol 
effects were evident from 15 minutes after injection, when mice 
ceased moving and increased respiration rates were observed. Most 
mice recovered within a few hours as judged by the return of normal 
feeding and grooming behaviour and were expected to not show any 
more clinical signs of treatment after 24h. Mortality was rare (cumu-
lative mortality over a year was estimated to be below 1%), occurs 
within the first day and is presumably because of acute arrhythmic 
problems. 80 and 160mg/kg isoproterenol induced significant in-
crease in cardiac troponin I (cTnI) in the serum 24h after injection 
(Figure 1A). cTnI is the current gold standard clinical biomarker for 
myocardial necrosis and allows detection of T2MI in the absence of 
CAD.6,37
80 and 160mg/kg isoproterenol also increased myocardial in-
filtration and fibrosis 2 weeks after injection (Figure 1B). Spleen/
bodyweight ratio as a measure of systemic inflammation and body-
weight as indicator of overall health were not affected with doses up 
to 160mg/kg (Figure 1C, D). 160mg/kg each on 2 subsequent days 
however increased spleen/bodyweight ratio and reduced body-
weight. A single injection of 160mg/kg was thus chosen as standard 
dose for subsequent experiments. Histopathological analysis of the 
hearts showed tissue damage resulting in granulation tissue and fi-
brosis. Consistent with catecholaminergic damage, injury was most 
prominent in the sub-endocardium (Figure 1E).
3.2 | Off-target histopathology in kidney, liver, 
lung and skeletal muscle is negligible
To define the degree of off-target damage to other organs, we per-
formed a thorough histopathological assessment of kidneys, liver, 
lung and skeletal muscle at weeks 1 and 2 after injection of 160mg/
kg isoproterenol. Myocardial infiltration and fibrosis were confirmed 
(Figure 2A). No pathological changes were observed in the other 
tested organs in any of the mice (n = 5/group) at week 1 (Figure 2B, 
C, S1). Although isoproterenol has been shown previously to induce 
acute necrosis in skeletal myocytes,38 the regenerative ability of 
skeletal muscle 39 appears to allow it to restore healthy morphology 
by week 1. At week 2, mild acute tubular injury and fibrosis were 
detectable in the kidneys (Figure 2B, C, S1). This thus happened after 
established cardiac damage. Renal damage has been documented as 
secondary to cardiac damage after experimental surgical LAD liga-
tion 40 and in human MI patients.41 The observed pattern of renal 
injury and fibrosis was therefore broadly consistent with the estab-
lished concept of cardiorenal syndrome, which is renal damage/dys-
function due to cardiac damage/dysfunction, and vice versa.42
3.3 | A single dose of 160mg/kg isoproterenol 
induces cardiac dilation and impairs systolic function 
in C57BL/6J mice
To assess whether immunopathology observed by histology was 
severe enough to affect cardiac morphology and function, we 
performed cardiac magnetic resonance (CMR) imaging before and 
2 weeks after isoproterenol injection. Previous studies using variable 
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F I G U R E  1   A single high dose of isoproterenol induces myocardial inflammation and fibrosis in C57BL/6J mice. Male C57BL/6J mice were 
treated with a single increasing dose of isoproterenol to induce myocardial ischaemia and cardiomyocyte necrosis and analysed 2 weeks 
after challenge. A, Serum cardiac troponin I (cTroponin I) levels to confirm myocardial injury. B, Infiltration and fibrosis were scored on a 
scale from 0 to 3 (none, mild, moderate, severe) in 4 fields of view in 2 heart cross sections at mid-level per mouse. C, Splenomegaly (spleen/
bodyweight ratio) as a measure of systemic immune activation. D, Change in bodyweight. E, Micrographs of H&E- and Picrosirius Red–
stained paraffin-embedded cross sections of the hearts showing mononuclear cell infiltration (H&E) and interstitial fibrosis (Picrosirius Red). 
Data are expressed as mean ± s.e.m., *P < .05, **P < .001, ***P < .0001 (B: non-parametric Kruskal-Wallis with Dunn's multiple comparisons 
post hoc test comparing each time-point to baseline. A, C and D: one-way ANOVA with Dunnett's multiple comparisons post hoc test 
comparing each time-point to baseline)
234  |     FORTE ET al.
     |  235FORTE ET al.
F I G U R E  2   A single high dose of isoproterenol does not affect liver, lung and skeletal muscle, but pathological changes in the kidneys 
are observed secondary to cardiac damage at week 2. Male C57BL/6J mice were treated with a single dose of isoproterenol to induce 
myocardial ischaemia and cardiomyocyte necrosis. A, Myocardial infiltration and fibrosis were scored on a scale from 0 to 3 (none, mild, 
moderate, severe) in 4 fields of view in 2 heart cross sections at mid-level per mouse. B, Kidney fibrosis was scored on a scale from 0 to 
3 (none, mild, moderate, severe) in 4 fields of view in 2 cross sections per mouse. n = 5/group, symbols represent individual mice. Data 
are expressed as mean ± s.e.m., *P < .05 (non-parametric Kruskal-Wallis with Dunn's multiple comparisons post hoc test comparing each 
time-point to baseline). C, Micrographs of H&E- and Picrosirius Red–stained paraffin-embedded sections of post-isoproterenol organs for 
assessment of mononuclear cell infiltration (H&E) and interstitial fibrosis (Picrosirius Red). Representative image shown
F I G U R E  3   Isoproterenol treatment causes significant volumetric changes in the heart and impaired systolic function. Male C57BL/6J 
mice were treated with a single dose of isoproterenol and analysed for cardiac morphology and function before and 2 weeks after 
isoproterenol challenge. A, Representative long-axis views (HLA and VLA) required for accurate planning of multi-stack short-axis CINE 
slices (grey lines). Each cardiac image was segmented at end diastole and end systole from base to apex to derive the outer and inner border 
of the left ventricle (LV) required for LV end-diastolic volume (EDV), LV end-systolic volume (ESV), LV ejection fraction (EF) and LV mass 
assessment. B, Quantification of LV EF pre- and 2 weeks post-isoproterenol administration. C, Representative images of end-systolic and 
end-diastolic hearts pre- and 2 weeks post-isoproterenol administration D, Quantification of LV EDV, ESV and mass pre- and 2 weeks post-
isoproterenol administration. n = 6/group, symbols represent individual mice before and after isoproterenol treatment. Values represent 
mean ± s.e.m.; *P < .05, **P < .005, one-tailed, paired Student's t test
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dosing regimens reported morphological changes and diastolic dys-
function.24,34,43 After planning of vertical long-axis (VLA) and hori-
zontal long-axis (HLA) cardiac views (Figure 3A), the endocardial and 
epicardial borders were contoured from apex to base at end-diastole 
and end-systole phases (Figure 3C). A mild but significant drop in left 
ventricular (LV) ejection fraction (Figure 3B) was detectable 2 weeks 
after isoproterenol treatment. This was paralleled by an increase in 
LV end-diastolic and end-systolic volumes (Figure 3D) suggestive of 
LV dilation. Isoproterenol administration did not cause significant al-
teration of LV mass by week 2 after treatment (Figure 3D).
3.4 | Model refinement and reduction in 
animal numbers
By convention, our first set of experiments was performed in male 
mice. However, considering a female dominance in autoimmune dis-
ease, immunological research is often performed in female mice. To 
reduce the number of surplus animals and ensure relevance to both 
sexes,44 we compared histology in isoproterenol-injected male and 
female mice. Results showed an equivalent level of cardiac histopa-
thology (Figure 4A, B) which allowed the use of female mice in sub-
sequent immunological experiments and will also support the use of 
both sexes in the future.
To further improve animal welfare benefits of the isoprotere-
nol model, we included pre-treatment with 0.05mg/kg buprenor-
phine for pain relief. Buprenorphine was injected subcutaneously 
30 minutes before isoproterenol administration. Manual mouse 
grimace scale (MGS) scoring was deemed not suitable, as no or-
bital tightening, or changes in nose and cheek bulge and whisker 
position were notable.45 Instead, we measured activity (moving, 
feeding, drinking, grooming) as a reliable sign of both the onset 
of and the recovery from acute isoproterenol effects (Figure 4C). 
Adding buprenorphine to the isoproterenol treatment shortened 
the average time to recovery by 20 minutes without affecting the 
degree of cardiac inflammatory and fibrotic damage (Figure 4D).
3.5 | A single high dose of isoproterenol triggers 
dendritic cell (DC) accumulation in the heart
Isoproterenol-induced cardiomyocyte damage leads to necrotic cell 
death,33 a potent trigger of innate immune responses initiating a clas-
sical wound healing response to remove cellular debris and restore 
tissue integrity.46 To investigate the composition of the myocardial 
immune cell infiltrate, we performed flow cytometry on single-cell 
suspensions of ventricular tissue 1 and 2 weeks after isoproterenol 
treatment (Figure 5A). As expected, the CD45+ myocardial immune 
cell population was increased 1 week after isoproterenol injection and 
was largely composed of myeloid cells, whereas total numbers of adap-
tive CD19+ B and CD3+ T lymphocytes remained stable (Figure 5B).
Dendritic cells are crucial in the induction of adaptive immune 
responses and autoimmunity because of their unique ability of ac-
tivating antigen-specific CD4+ helper T cells.47 Their numbers peak 
1 week after ischaemic damage induced by surgical LAD ligation in 
mice.48 Numbers of CD11c+ DC were significantly increased after 
1 week in isoproterenol-treated hearts, confirming this timing in the 
isoproterenol model. Importantly, increased DC number is the first 
F I G U R E  4   Opportunities for refinement and reduction in the 
isoproterenol-induced T2MI model. Male and female C57BL/6J 
mice were treated with a single dose of isoproterenol to induce 
myocardial ischaemia and cardiomyocyte necrosis. A, B, Myocardial 
infiltration (A) and fibrosis (B) were scored on a scale from 0 to 
3 (none, mild, moderate, severe) in 4 fields of view in 2 heart 
cross sections at mid-level per mouse. n = 3-5/group, symbols 
represent individual mice. C, D, Female C57BL/6J mice were 
treated with a single dose of isoproterenol with and without 
0.05mg/kg buprenorphine to induce myocardial ischaemia and 
cardiomyocyte necrosis under analgesia. C, Count of animals with 
normal movement and activity and average time until recovery 
of normal activity pattern. D, Infiltration and fibrosis in cardiac 
tissue sections 2 weeks after isoproterenol injection. n = 3/group, 
symbols represent individual mice. Histopathology scoring data are 
expressed as mean ± s.e.m., *P < .05 (A, B: two-way ANOVA with 
Sidak's multiple comparison post hoc test comparing each group to 
each other. D: non-parametric Kruskal-Wallis with Dunn's multiple 
comparisons post hoc test comparing each time-point to baseline)
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step towards the induction of an adaptive immune response and au-
toimmunity against the heart.
3.6 | Myocardial CD4+ helper T cells are activated 
in response to a single high dose of isoproterenol
To investigate whether early DC activation in response to isoproterenol-
induced cardiomyocyte necrosis is sufficient to trigger a downstream 
adaptive immune response, we performed a refined analysis of the 
myocardial CD4+ T cell phenotype by staining for the surface markers 
CD44 and CD62L which allow distinction between effector and naïve T 
cells. Although the total fraction of CD4+ T cells remained unchanged 
(Figure 5C), an increase in activated CD62L-CD44- effector cells is ap-
parent (Figure 5D). We also find activated CD4+ T cells in the mediastinal 
lymph nodes of male mice (Figure S2) showing relevance of these pro-
cesses for both sexes. This confirms persistent activation of the adaptive 
immune system in response to isoproterenol-induced myocardial injury.
F I G U R E  5   Myocardial CD45+ immune cell infiltrate in response to a single dose of 160mg/kg isoproterenol. Female C57BL/6J mice were 
treated with a single dose of isoproterenol to induce myocardial ischaemia and cardiomyocyte necrosis, and flow cytometry was performed 
on single-cell preparations of heart ventricles 1 and 2 weeks after isoproterenol injection. A, Representative dot plots showing the flow 
cytometry gating strategy to obtain total CD45+, CD3+, CD19+, CD11b+ and CD11c+ populations. B, Quantification of the total number of 
CD45+, CD3+, CD19+, CD11b+ and CD11c+ cells per mg ventricular tissue in isoproterenol-treated versus control mice. n = 8/group, symbols 
represent individual mice. C, Quantification of the fraction of CD4+ T cells among total T cells in the ventricular tissue of isoproterenol-treated 
versus control mice. D, Representative contour plots of CD62L and CD44 staining of CD3+ CD4+ T cells and corresponding quantification of 
the CD62L-CD44- subpopulation of effector T cells in isoproterenol-treated versus control mice. n = 4-5/group, symbols represent individual 
mice. Data are expressed as mean ± s.e.m., *P < .001, **P < .05, ****P < .0001 (B: one-way ANOVA with Dunnett's multiple comparisons post 
hoc test comparing each time-point to baseline. C, D: one-tailed unpaired Student's t test with Welch's correction)
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3.7 | Isoproterenol treatment triggers the 
production and in vivo deposition of mature anti-
heart auto-antibodies
Activated autoreactive CD4+ helper T cells induce B cells to generate 
mature auto-antibodies, which are a hallmark sign of an established 
autoimmune response. We found a significant amount of mature IgG 
deposited in the myocardium 4 weeks after isoproterenol injection 
(Figure 6A, B). The linear deposition pattern followed the myocyte 
fibres and the inner lining of blood vessels. In particular, vessels sur-
rounded by perivascular infiltrate appeared affected. In addition, a 
small number of IgG+ cells, presumably mature B cells, were found 
in both baseline and isoproterenol-treated tissue. We further tested 
post-isoproterenol serum at week 2 (acute) and week 12 (chronic) for 
the persistent presence of anti-heart auto-antibodies. We found a 
significant increase in auto-antibody levels at chronic stage after iso-
proterenol injection (Figure 6C). Importantly, these auto-antibodies 
are of the mature class-switched IgG isotype as present in estab-
lished and persistent adaptive immune responses.
This confirms that mature autoreactive B cells persist for an ex-
tended period after initial damage and produce class-switched au-
to-antibodies against the heart, which deposit on cardiomyocytes 
and endothelial cells in vivo, which is the prerequisite for auto-anti-
body–mediated tissue damage.
3.8 | Adoptive transfer of splenocytes from 
isoproterenol-treated C57BL/6J mice is sufficient to 
induce LV dilation and functional decline
Adoptive transfer of autoreactive immune cells is a well-established 
strategy to prove their pathological effects isolated from potential 
confounding factors because of the initial experimental challenge. 
A recent report shows that splenic T cells isolated from C57BL/6 
mice subjected to permanent coronary ligation induce LV remodel-
ling upon transfer into healthy recipient mice.49
To show whether immunopathology is also transferable in iso-
proterenol-induced T2MI, we performed an adoptive transfer of 
total splenocytes, splenic CD4+ T cells (T cell–mediated damage) or 
serum (auto-antibody mediated damage) from isoproterenol-treated 
mice 4 weeks post-injection, to healthy syngeneic recipients. 
Splenocytes were used because of the obtainable numbers and after 
confirmation that an increase in the CD44-CD62L- effector subpop-
ulation is also observed in splenic CD4+ T cells (Figure 7A).
A single intravenous transfer of 3x107 splenocytes from iso-
proterenol-treated mice affected global cardiac function as shown 
by a drop in LV ejection fraction 4 weeks after transfer (Figure 7B). 
This functional impairment was likely because of impaired contrac-
tility and dilation as LV volumes increased in recipients of isoprotere-
nol-splenocytes (Figure 7C). Notably, transfer of 1x107 isolated 
CD4+ T cells only partially recapitulated the effects of total sple-
nocytes and we did not observe any differences between control 
groups and mice treated with serum from isoproterenol-injected 
donor mice (Figure 7B, C).
This confirms that besides acute myocardial necrosis and subse-
quent fibrotic tissue repair, isoproterenol injection triggers the devel-
opment of long-term autoimmunity capable of inducing heart damage 
and affecting cardiac function. This is likely a multi-dimensional pro-
cess caused by the interplay between several immune cells and factors.
4  | DISCUSSION
Here, we show that T2MI-like necrotic lesions induced by a single 
high dose of the synthetic catecholamine isoproterenol trigger per-
sistent adaptive immunopathology in the heart (Figure 8)
F I G U R E  6   A single dose of isoproterenol triggers production of anti-heart auto-antibodies. Female C57BL/6J mice were treated with 
a single dose of 160mg/kg isoproterenol to induce myocardial ischaemia and cardiomyocyte necrosis, and the heart and serum were 
obtained for analysis of anti-heart auto-antibody production. A, Quantification of mean fluorescence intensity (MFI). B, Example image of 
immunofluorescence staining of frozen heart sections of isoproterenol-treated mice 4 weeks after challenge, using goat anti-mouse IgG-
FITC and rat anti-mouse IgM-PE to detect in vivo deposits of anti-heart auto-antibodies, green: IgG, red: IgM, blue: DAPI (nuclei). n = 4-9/
group. C, Levels of anti-cardiac auto-antibodies in the serum over time as tested by ELISA using serum of isoproterenol-treated mice against 
rat cardiac lysate. n = 5-6/group, symbols represent individual mice. Data are expressed as mean ± s.e.m., **P < .001, ****P < .0001 (one-
way ANOVA with Dunnett's multiple comparisons post hoc test comparing each time-point to baseline)
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F I G U R E  7   Adoptive transfer of splenocytes from isoproterenol-injected donor mice leads to LV dilation and impairs cardiac function. 
Female donor C57BL/6J mice were treated with a single dose of isoproterenol to induce myocardial ischaemia and cardiomyocyte necrosis. 
Serum was collected and splenocytes and CD4+ T cells isolated after 4 weeks. A, Representative contour plots of CD62L and CD44 staining 
of splenic CD3+ CD4+ T cells and corresponding quantification of the CD62L-CD44- subpopulation of effector T cells in isoproterenol-
treated versus control mice. n = 4-5/group, symbols represent individual mice. Recipient mice were treated with an intravenous injection of 
3x107 control (ctrl-spleno) or ISO-splenocytes (ISO-spleno), 1x107 ISO-T cells or a twice-weekly intraperitoneal injection of 200ul ISO-serum 
for 2 weeks. B, C, Echocardiography to assess global LV function (LV ejection fraction, B) and heart morphology (end-systolic and end-
diastolic volumes, C) was performed after 4 weeks. Data are expressed as mean ± s.e.m., *P < .001, **P < .05, ****P < .0001 (A: one-tailed 
unpaired Student's t test with Welch's correction. B, C: one-way ANOVA with Dunnett's multiple comparisons post hoc test comparing each 
group to ctrl-spleen)
F I G U R E  8   Isoproterenol-induced 
cardiomyocyte necrosis leads to the 
passive release of alarmins and antigens 
including cardiac troponin I, which is used 
as serum biomarker for cardiac damage. 
Pro-inflammatory alarmins trigger acute 
innate immune cell infiltration including 
DC at week 1 after isoproterenol 
challenge. Interstitial fibrosis and 
morphological and functional changes 
are also observed at this time. Myocardial 
DC activate auto-reactive effector T cells 
in the mediastinal lymph nodes. Effector 
T cells in turn induce B cells to generate 
mature auto-antibodies that deposit along 
myocardial fibers.
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The definition of myocardial infarction differentiates patients 
with MI because of coronary occlusion and plaque rupture (T1MI) 
from those with myocardial necrosis because of oxygen sup-
ply-demand imbalance (T2MI).50,51 Myocardial necrosis without 
symptoms or signs of myocardial ischaemia is classified as acute 
or chronic myocardial injury. Both myocardial injury and T2MI 
are common, yet these patients have poor short-term and long-
term outcome 7,51 with a heart failure risk comparable to T1MI.8 
Injection of a single high dose of isoproterenol mimics an exces-
sive activation of the adrenergic system and leads to sympathetic 
overstimulation of the heart. This can be observed during criti-
cal illness in human patients 52 including those with takotsubo 
syndrome 53,54 and in septic patients 55 or those receiving cate-
cholamines for cardiac pacing or inotropic support. Detrimental 
effects of excess catecholamines on the heart include impaired 
diastolic function, tachycardia and tachyarrhythmia.52 The conse-
quent imbalance between myocardial oxygen supply and demand, 
dysregulation of calcium handling and the resulting degree and 
pattern of myocardial necrosis, inflammatory infiltration and re-
placement fibrosis are reminiscent of the myocardial damage in-
curred by human T2MI. Notably, the autonomous nervous system 
and aberrant adrenergic stimulation of the heart have also been 
suggested as a clinically targetable pathological factor after myo-
cardial infarction 56 and in the development of heart failure.57,58
Concerns about off-target damage to other organs have pre-
viously hampered acceptance of the isoproterenol model. Using 
our treatment regimen, these appear uncalled-for as no direct iso-
proterenol-induced pathological changes were observed in liver, 
lung and skeletal muscle. Damage to the kidneys was of particular in-
terest as there are a range of isoproterenol-activated pathways that 
may sensibly be assumed to cause kidney injury. For example, iso-
proterenol-induced activation of the renin-angiotensin cascade may 
lead to liberation of angiotensin II,59 which can cause renal vaso-
constriction driving ischaemia and fluid overload and promotes renal 
oxidative stress, inflammation and fibrosis.60 However, because of 
belated onset, the mild acute tubular injury and fibrosis detected in 
the kidneys 2 weeks after treatment are most consistent with car-
diorenal syndrome, a positive feedback loop in which a damaged 
heart leads to renally mediated fluid retention, which then further 
aggravates the underlying heart dysfunction.42
The immune response following myocardial injury has received 
significant attention recently. It is initiated by the release of dan-
ger-associated molecular patterns (DAMPs) from necrotic cardio-
myocytes, which activates a highly orchestrated innate immune 
reaction 46 for the quick removal of necrotic debris and restoration 
of tissue integrity. The interplay between innate immune cells and 
fibroblast plays a crucial role in the ensuing scar formation. Although 
this immediate wound healing response is critical for acute sur-
vival, the heart appears susceptible to persistent immunopathology 
presumably because of an adaptive autoimmune response against 
cardiac antigens including most prominently cardiac myosin.61 This 
anti-heart autoimmune response has recently become the focus 
of studies into how the immune system affects the heart after 
ischaemic damage. Both autoreactive B and T cells have been de-
tected after myocardial damage in mouse models 62,63 and human 
patients.64,65
We show here that isoproterenol-induced myocardial necrosis 
triggers dendritic cell expansion in the myocardium and T cell acti-
vation in the mediastinal lymph nodes. Activated T cells stimulate B 
cells to produce mature IgG anti-heart auto-antibodies against the 
heart, a sign of a bona fide autoimmune response. Importantly, we 
confirm cell-mediated immunopathology against the heart by adop-
tive transfer of splenocytes from T2MI mice.
Anti-heart auto-antibodies indicating autoimmunity have thus 
far been demonstrated in a wide range of human heart conditions 
66 and are likely because of high amounts of cardiac antigen in an 
inflammatory environment overwhelming immunological tolerance. 
Importantly, the adaptive immune system is activated by antigens 
released from necrotic cells irrespective of the initial cause of necro-
sis. Accordingly, we found anti-heart auto-antibodies in experimen-
tal models after surgical induction of T1MI via LAD ligation 16 and 
under systemic inflammatory conditions,30 as well as in the present 
study after chemical induction of T2MI-like myocardial necrosis. 
The common factor in these situations is myocardial necrosis, which 
is sufficient to induce a downstream adaptive immune response 
against the heart.
Autoimmunity against the heart causes persistent myocar-
dial immunopathology and ongoing tissue degeneration, which 
exacerbates development towards heart failure.67 Underlying 
pathological mechanisms are still far from understood, but the 
isoproterenol model provides an opportunity to study these pro-
cesses in T2MI-like heart disease. Simplicity and resource effi-
ciency will allow thorough investigation of a range of aspects that 
likely affect short- and long-term outcome in T2MI patients in-
cluding investigation of (a) the local innate immune response in 
the myocardium, (b) the role of lymphatics and fibroblasts in post-
T2MI autoimmunity,68,69 (c) the influence of genetics on the risk of 
developing heart failure after T2MI 34 and (d) how all of the above 
can be targeted for improved therapeutics.
4.1 | Study limitations
Immune cells express adrenoreceptors,70,71 and long-term isopro-
terenol treatment regimens increase circulating immune cells.72 
Because of an in vivo half-life of less than 5 minutes, the effects of a 
single acute isoproterenol injection are expected to have worn off by 
the time cardiomyocytes develop necrosis and the immune system is 
recruited.73 However, an effect on the early immune response can-
not be fully excluded and should be considered when studying very 
early responses.74
Our adoptive transfer experiment indicates a role of CD4+ T 
cells in cardiac immunopathology, but as expected they are not 
the sole pathogenic factor. Serum transfer (to test the role of 
circulating auto-antibodies) failed to induce a cardiac phenotype 
which may have several technical (eg insufficient amount of serum 
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transferred) and/or biological reasons (e.g. majority of anti-heart 
auto-antibodies are bound to donor myocardium, 4 weeks are not 
enough to show pathology or isolated auto-antibodies are not 
pathological). Further studies are therefore needed for conclusive 
information on which cell type and/or factor has true pathological 
function in driving LV dilation and heart failure. Heart failure is a 
complex condition, and it is anticipated that the majority of im-
mune cells will be involved.
This study did not investigate the effects of isoproterenol on the 
brain. Researchers wishing to address the neurological aspects of 
T2MI are encouraged to first investigate off-target brain histopa-
thology and damage markers.
The degree of isoproterenol-induced immunopathology and re-
placement fibrosis, and other physiological effects of catecholamines 
are variable between mouse strains.75,76 Although this opens exciting 
opportunities for genetic mapping of variable traits, we recommend 
performing a dose titration experiment for new strains. C57BL/6J 
mice have a robust cardiac phenotype and are relatively resistant 
to myocardial fibrosis.34,35 It is anticipated that other strains may be 
more susceptible to isoproterenol effects and a dose titration exper-
iment will be necessary to maintain welfare standards.
The decline of global cardiac function we observed in this study 
in C57BL/6J mice was significant but mild compared to clinical defi-
nitions of human heart failure both with reduced and preserved 
ejection fraction.77 Other mouse strains may react with a more pro-
nounced functional phenotype.
The role of fibroblasts and other cardiac resident cell types has 
not been investigated in this study. However, the specific contribu-
tion of fibroblasts to histopathology may vary between isoprotere-
nol-induced T2MI and other types of cardiac damage such as LAD 
ligation-induced T1MI or experimental autoimmune myocarditis and 
is worth exploring further.78
Several additional factors that might affect the response to iso-
proterenol treatment have not been investigated systematically in-
cluding age and potential age-dependent sex differences, circadian 
rhythm and seasonality, as well as holding conditions (e.g. SPF versus 
conventional animal facility affecting microbiome).
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 76. Nieto-Lima B, Cano-Martínez A, Rubio-Ruiz ME, Pérez-Torres I, 
Guarner-Lans V. Age-, Gender-, and in vivo different doses of iso-
proterenol modify in vitro aortic vasoreactivity and circulating 
VCAM-1. Front Physiol. 2018;9:20.
 77. Metra M, Dinatolo E, Dasseni N. The new heart failure associa-
tion definition of advanced heart failure. Cardiac Failure Review. 
2019;5(1):5.
 78. Forte E, Skelly DA, Chen M, et al. Dynamic interstitial cell response 
during myocardial infarction predicts resilience to rupture in genet-
ically diverse mice. Cell Rep. 2020;30(9):3149-3163 e6.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Forte E, Panahi M, Baxan N, et al. 
Type 2 MI induced by a single high dose of isoproterenol in 
C57BL/6J mice triggers a persistent adaptive immune 
response against the heart. J. Cell. Mol. Med.. 2021;25:229–
243. https://doi.org/10.1111/jcmm.15937
